The prescription foundation of male HRT — how TRT works, what clinical dosing looks like, and how to find a qualified provider who actually runs the right labs.
Testosterone replacement therapy (TRT) restores testosterone levels in men with clinically low production. The two most common injectable esters are testosterone cypionate (Depo-Testosterone) and testosterone enanthate (Delatestryl) — functionally interchangeable, with slightly different release kinetics.
TRT is a prescription medication in the US, classified as a Schedule III controlled substance. It should only be used under the supervision of a licensed provider who has confirmed clinically low testosterone through repeated labs and appropriate symptom evaluation.
FDA approved (Schedule III). Prescription only. WADA prohibited (S1 — Anabolic Agents). StackTrax does not sell or facilitate purchase of TRT.
Exogenous testosterone binds androgen receptors throughout the body — muscle, bone, brain, fat, skin. Drives the anabolic and masculinizing effects.
The cypionate / enanthate ester slows release from the injection depot. Cypionate has a slightly longer half-life (~8 days) vs enanthate (~5 days) — functionally similar at weekly or twice-weekly injections.
Exogenous testosterone signals the hypothalamus to stop producing LH and FSH, which shuts down the testes’ own testosterone and sperm production. This is why TRT usually reduces fertility and testicular size — and why HCG is often added to preserve both.
Some testosterone converts to estradiol via the aromatase enzyme. Too little or too much estradiol both cause problems. Many patients don’t need an AI; those who do use low-dose anastrozole under a provider’s guidance.
TRT has decades of clinical use and is one of the most-studied hormonal therapies. The benefits are consistent when testosterone is actually low and the therapy is done properly.
| Benefit | Evidence |
|---|---|
| Energy & mood | Weaker than commonly claimed. In the T-Trials (Snyder 2016, PMID 26886521) testosterone produced no significant benefit for vitality on the FACIT-Fatigue scale. Mood and depressive symptoms improved only slightly |
| Libido & erectile function | The most reliable benefit. T-Trials: significantly increased sexual activity (p < 0.001), sexual desire and erectile function (PMID 26886521) |
| Lean mass & strength | Consistent gains in lean mass. Function is less certain: in the T-Trials the 6-minute-walk improvement missed significance in the Physical Function Trial itself and reached it only when all three trials were pooled (20.5% vs 12.6%, p = 0.003) |
| Bone density | BMD improves — but the outcome that matters did not. In the TRAVERSE fracture subtrial (Snyder 2024, PMID 38231621), 5,204 men over 3.19 years, fractures were more common on testosterone: 3.50% vs 2.46%, HR 1.43 (95% CI 1.04–1.97). See the evidence section |
| Insulin sensitivity | Improvements in metabolic syndrome markers |
| Cognition | Modest improvements in spatial/verbal memory at restored levels |
Build your protocol, log every dose, monitor your body's response, and get reminders so you never miss a dose.
Start Tracking FreeTRT is genuinely well studied, and two very large trials published since most online guides were written have changed what can honestly be said about it. Both are worth knowing in detail, because both are routinely quoted for only half of what they found.
The trial the field waited two decades for. 5,246 men aged 45–80 with hypogonadal symptoms, two fasting testosterone readings under 300 ng/dL, and pre-existing or high risk of cardiovascular disease — deliberately the population most likely to show harm. Randomised to daily 1.62% testosterone gel titrated to 350–750 ng/dL, or placebo. Mean follow-up 33 months.
Major adverse cardiac events occurred in 182 men (7.0%) on testosterone and 190 (7.3%) on placebo — hazard ratio 0.96 (95% CI 0.78–1.17), meeting non-inferiority. On the question of heart attacks, strokes and cardiovascular death, that is about as reassuring as trial evidence gets.
The part usually left out. The same trial found a higher incidence of atrial fibrillation, acute kidney injury, and pulmonary embolism in the testosterone group. "TRAVERSE showed TRT is cardiovascularly safe" is true for the primary endpoint and incomplete as a summary. Anyone with a history of AF or clotting should be having a different conversation than the headline implies.
Testosterone improves bone mineral density; that has been known for years, and it is why bone protection appears on every benefits list including, until now, ours. So this subtrial was expected to confirm fewer fractures.
It found the opposite. Among 5,204 men followed a median of 3.19 years, clinical fractures occurred in 91 men (3.50%) on testosterone versus 64 (2.46%) on placebo — HR 1.43 (95% CI 1.04–1.97), with the incidence appearing higher on testosterone across every fracture endpoint examined. The authors' conclusion is that testosterone did not lower fracture incidence.
This is the density-versus-outcome gap in its clearest form: the biomarker moved in the expected direction and the clinical event moved the wrong way. Denser bone is not the goal; unbroken bone is. Bone protection should not be a reason to start TRT.
Seven coordinated placebo-controlled trials in symptomatic men 65 and older. Sexual function improved clearly and consistently — activity, desire and erectile function all significantly better. Vitality did not improve significantly, mood and depressive symptoms improved only slightly, and physical function reached significance only in the pooled analysis rather than in the trial designed to test it.
If you take one thing from this: the "energy" claim that sells TRT is the claim with the weakest support, and the sexual-function benefit that men often mention last is the one that is best established.
None of the above argues against TRT for men with genuine, confirmed hypogonadism — treating a real deficiency remains well supported, and TRAVERSE substantially retired the older cardiovascular scare. What the evidence does not support is TRT as a general-purpose vitality, longevity or bone-protection intervention in men whose testosterone is not actually low.
Not medical advice. These are prescription medications. The figures below describe established clinical practice and labelled prescribing information — they are not a recommendation, they do not account for your labs, history, or other medications, and safe use depends on monitoring a page cannot do. Work with a qualified healthcare provider.
Dose is personalized. Your provider titrates based on trough labs, symptoms, and side effects. Note: weekly or twice-weekly dosing is a modern practice to smooth peak-to-trough levels — historically, cypionate / enanthate were dosed every 2–3 weeks (PMID 19011287), though that schedule often leaves levels out of the physiological range >50% of the time. More frequent injections are the reason your provider is likely choosing weekly or twice-weekly.
IM vs. SubQ — actual PK differences: Choi 2022 (PMID 34694927) compared 234 hypogonadal men on 100 mg/week IM testosterone cypionate against a subcutaneous testosterone enanthate autoinjector at the same dose. Trough total testosterone rose similarly on both, and modality was not independently associated with TT (p = 0.057). The subcutaneous route was independently associated with lower estradiol and lower haematocrit (both p < 0.001). PSA did not differ between routes (p = 0.965) — this guide previously listed PSA alongside E2 and haematocrit, which reversed the study’s actual finding on that marker. Route choice should factor into how closely these labs are monitored, and may influence whether an AI, phlebotomy, or urology workup becomes necessary.
The diagnostic and monitoring standard below follows the Endocrine Society clinical practice guideline (Bhasin 2018, PMID 29562364), which requires symptoms plus repeated low morning fasting total testosterone before therapy starts, not a single reading.
Pre-filled with a typical Testosterone Replacement (Cypionate / Enanthate) setup. Edit any field — the draw updates live.
Insulin syringe — 100 units = 1 mL
Free account. Saves your reconstitution + schedules doses + tracks every vial.
Dosing cheat sheet, reconstitution reference, and cycle planning — delivered to your inbox.
Testosterone Replacement (Cypionate / Enanthate) is a prescription medication. StackTrax does not sell, prescribe, or facilitate purchase of prescription drugs.
Find a clinician who can order baseline lab work, screen for contraindications, monitor your response, and adjust dosing over time. Options to consider:
Before starting, you’ll typically want:
Avoid sources that offer prescription medications without labs, medical history, or licensed-provider oversight. If a telehealth service promises a prescription after a 5-minute questionnaire, that’s a red flag.
Build your protocol, log every dose, monitor your body's response, and get reminders so you never miss a dose.
Start Tracking FreeFor most men who start TRT for genuine clinical hypogonadism, yes. Exogenous testosterone suppresses the hypothalamic-pituitary-gonadal axis, shutting down the testes' own production. Once on TRT, your natural production won't simply resume when you stop unless you actively restart the axis with adjuncts like HCG and SERMs (clomid, enclomiphene). Some men do come off TRT successfully, but it requires a structured restart protocol and there's no guarantee natural production returns to pre-treatment levels.
Cardiovascular risk has been debated in the literature, but recent data is largely reassuring at therapeutic doses. The key qualifier is therapeutic doses — pushing total testosterone supraphysiologically high or letting hematocrit climb above 54% does add cardiovascular risk. Active uncontrolled heart failure is a contraindication. Standard monitoring catches the relevant signals (hematocrit, lipids, blood pressure) long before they become dangerous.
No. TRT restores testosterone to the physiological range (target ~600-900 ng/dL trough) in men with clinically low production, using doses around 100-200 mg/week. Anabolic steroid abuse typically uses supraphysiological doses (often 500-1000+ mg/week, stacked with other compounds) aimed at performance enhancement, not replacement. The mechanism is the same hormone, but the dose and intent differ substantially. TRT is FDA-approved as a Schedule III prescription medication used under provider supervision.
TRT does not cause prostate cancer based on current evidence, but active prostate cancer is an absolute contraindication because testosterone can fuel existing disease. Family history of prostate cancer is a use-caution flag, not a hard no. TRT does cause benign prostate volume increase, and BPH with significant urinary symptoms is another use-caution scenario. Standard monitoring includes baseline and ongoing PSA.
Stopping TRT without a restart protocol typically leaves men with hypogonadal levels for an extended period because the HPG axis stays suppressed. A structured restart usually combines HCG (to wake up the Leydig cells) with a SERM like clomid or enclomiphene (to restart endogenous LH/FSH production). This is provider-directed territory. Some men recover full endogenous production; others find their natural levels never return to pre-TRT baselines.
Yes. Exogenous testosterone signals the hypothalamus to stop producing LH and FSH, which shuts down the testes' own testosterone and sperm production. This is why TRT usually reduces fertility and testicular size. HCG (500-1500 IU 2-3x/week) is commonly added to TRT protocols specifically to preserve testicular size and fertility by directly stimulating the Leydig cells, bypassing the suppressed axis.
Disclaimer: This guide is for educational and informational purposes only and is not intended as medical advice, diagnosis, or treatment. The compounds discussed are not FDA approved for human use. Always consult a qualified healthcare provider before starting any new supplement or peptide protocol. StackTrax does not sell peptides or supplements directly — purchase links go to third-party vendors. StackTrax is not responsible for the products, quality, or business practices of any third-party vendor.
© 2026 StackTrax, LLC. All rights reserved.
Privacy · Terms · Do Not Sell or Share My Personal Information
StackTrax guides cover peptides and compounds that are not FDA-approved for the uses discussed. The dosing, reconstitution, and safety information is compiled from published research and community protocols for educational purposes only.
Before using any compound mentioned here, consult a qualified healthcare provider. StackTrax does not sell, prescribe, or recommend these substances for personal use.